Assertio Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Assertio Therapeutics (ASRT) Misses Q3 EPS by 10c, Revenues Beat
November 6, 2020 6:17 AM ESTAssertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of ($0.09), $0.10 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $34.57 million versus the consensus estimate of $32.5 million.
Reported Net Product Sales of $34.3 MillionNon-GAAP Net Product Sales of $33.7 Million; Increased 21.4% over Pro-Forma Second Quarter 2020Non-GAAP Net Product Sales Consistent with Pro-Forma Prior Year Quarter Despite COVID-19 Related Sales Disruptions and Effects of Sales Force IntegrationProvides Updated Outlook for Remainder of 2020We are proud of what we have achieved so far this year, as we... More
